5 results
Objectives: The following trial objectives for adolescent patients (from 12 and up to 18 years of age) with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:* Assess the effect of eculizumab on TMA-Event Free status…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
Objectives: The following trial objectives for adult patients with plasma therapy-resistantAtypical Hemolytic-Uremic Syndrome (aHUS) are to:Primary:• Assess the effect of eculizumab to reduce thrombotic microangiopathy (TMA) asindicated by…
To investigate the clinical efficacy in detecting clinically relevant arritmia's (especially AF) of the Reveal XT in patients with mild to moderate heart failure and elevated risk factor for stroke and TIA (CHADS score), currelently not treated…
To show a non-inferiority of continuous use of oral contraceptives for three months to long term pituitary down-regulation with a GnRH agonist for three months prior to present-day IVF/ICSI protocols in patients with severe endometriosis (ASRM…